公开(公告)号：US20240417455A1

公开(公告)日：2024-12-19

申请号：US18817360

申请日：2024-08-28

Applicant: MORPHOSYS AG

Inventor： Stefan HARTLE ,  Stephane LECLAIR ,  Amgad SHEBL ,  Stefan STEIDL ,  Bodo BROCKS ,  Daniela Della DUCATA ,  Kai ROSPORT

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20210130451A1

公开(公告)日：2021-05-06

申请号：US17144685

申请日：2021-01-08

Applicant: MORPHOSYS AG

Inventor： Stefan HARTLE ,  Stephane LECLAIR ,  Amgad SHEBL ,  Stefan STEIDL ,  Bodo BROCKS ,  Daniela Della DUCATA ,  Kai ROSPORT

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.